Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Special Report
  • Published:

Ten years after the first inspection of a candidate European centre, an EBMT registry analysis suggests that clinical outcome is improved when hematopoietic SCT is performed in a JACIE accredited program

Bone Marrow Transplantation volume 47, pages 15–17 (2012)Cite this article

Abstract

In 2010, JACIE, the Joint Accreditation Committee of ISCT (International Society for Cell Therapy) Europe and EBMT (European group for Blood and Marrow Transplantation) celebrated the tenth anniversary of the first inspection of a European hematopoietic SCT program. JACIE standards establish the criteria for a comprehensive quality management program that covers all three major domains of activity that are necessary for the delivery of HSCT: clinical, collection and processing, as well as their interactions with ancillary and supportive activities. Although more than 200 European programs have applied for JACIE accreditation, and more than 100 have been granted accreditation, a recent retrospective analysis of the large-size EBMT registry of autologous and allogenic hematopoietic HSCT demonstrates that one of the factors affecting the overall survival of recipients of allogenic transplantation is the status of the transplant program regarding JACIE accreditation. This provides one of the first demonstrations that introduction of a quality management system contributes to the overall survival of patients treated with a highly specific medical procedure, and represents a milestone in the implementation of JACIE.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Pamphilon D, Apperley JF, Samson D, Slaper-Cortenbach I, McGrath E . JACIE accreditation in 2008: demonstrating excellence in stem cell transplantation. Hematol Oncol Stem Cell Ther 2009; 2: 311–319.

    Article  PubMed  Google Scholar 

  2. LeMaistre CF, Loberiza Jr FR . What is quality in a transplant program? Biol Blood Marrow Transplant 2005; 11: 241–246.

    Article  PubMed  Google Scholar 

  3. Gratwohl A, Baldomero H . Trends of hematopoietic stem cell transplantation in the third millennium. Curr Opin Hematol 2009; 16: 420–426.

    Article  PubMed  Google Scholar 

  4. Gratwohl A, Baldomero H, Frauendorfer K, Rocha V, Apperley J, Niederwieser D . The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. Bone Marrow Transplant 2008; 41: 687–705.

    Article  CAS  PubMed  Google Scholar 

  5. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A et al. Hematopoietic stem cell transplantation: a global perspective. Jama 2010; 303: 1617–1624.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A, Niederwieser D . Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 2007; 39: 71–87.

    Article  CAS  PubMed  Google Scholar 

  7. Gratwohl A, Baldomero H, Schwendener A, Rocha V, Apperley J, Frauendorfer K et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 2009; 43: 275–291.

    Article  CAS  PubMed  Google Scholar 

  8. Apperley J . Just another cost increasing exercise (JACIE)? Bone Marrow Transplant 2004; 34: 835–838.

    Article  CAS  PubMed  Google Scholar 

  9. Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, deWitte T et al. Impact of JACIE accreditation on outcome after haematopoietic stem cell transplantation: an EBMT megafile registry based analysis. Bone Marrow Transplant [Abstract]. 2010; 45 (Suppl 2): S63 (Abstract).

    Google Scholar 

  10. Afolalu B, Troidle L, Osayimwen O, Bhargava J, Kitsen J, Finkelstein FO . Technique failure and center size in a large cohort of peritoneal dialysis patients in a defined geographic area. Perit Dial Int 2009; 29: 292–296.

    PubMed  Google Scholar 

  11. Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the acute leukemia and pediatric disease working parties of the European blood and marrow transplant group. Blood 2010; 115: 3437–3446.

    Article  CAS  PubMed  Google Scholar 

  12. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.

    Article  CAS  PubMed  Google Scholar 

  13. Stem Cell Trialist's Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074–5087.

  14. Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962–2971.

    Article  CAS  PubMed  Google Scholar 

  15. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620–1629.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. C Chabannon, C Lamers, F Lanza and I Slaper-Cortenbach: Authors this manuscript on behalf of ISCT Europe.

  2. D Pamphilon: Medical Director for JAICE.

  3. C Vermylen: Chair of the Accrediation Commitee.

  4. A Gratwohl, D Niederwieser, A Madrigal and J Apperley: Authors this manuscript on behalf of EBMT.

  5. E McGrath: Heads the Accreditation Office.

Authors and Affiliations

  1. Institut Paoli-Calmettes and Inserm CIC-B510, Marseille, France

    C Chabannon

  2. JACIE Accreditation Office, Barcelona, Spain

    C Chabannon, D Pamphilon, C Vermylen, E McGrath & J Apperley

  3. National Health Service Blood and Transplant, Bristol, UK

    D Pamphilon

  4. Université Catholique de Louvain, Bruxelles, Belgium

    C Vermylen

  5. University Hospital, Basel, Switzerland

    A Gratwohl

  6. University Hospital, Leipzig, Germany

    D Niederwieser

  7. Erasmus University Medical Center, Rotterdam, The Netherlands

    C Lamers

  8. Cremona Hospital, Cremona, Italy

    F Lanza

  9. Utrecht University Medical Center, Utrecht, The Netherlands

    I Slaper-Cortenbach

  10. Anthony Nolan Research Institute, Royal Free Hospital, Hampstead, UK

    A Madrigal

  11. Hammersmith Hospital, London, UK

    J Apperley

Authors
  1. C Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Pamphilon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Vermylen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Gratwohl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Niederwieser
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E McGrath
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Lamers
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F Lanza
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. I Slaper-Cortenbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Madrigal
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J Apperley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Chabannon.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chabannon, C., Pamphilon, D., Vermylen, C. et al. Ten years after the first inspection of a candidate European centre, an EBMT registry analysis suggests that clinical outcome is improved when hematopoietic SCT is performed in a JACIE accredited program. Bone Marrow Transplant 47, 15–17 (2012). https://doi.org/10.1038/bmt.2011.32

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.32

Keywords

This article is cited by

Search

Advanced search

Quick links